MK-4409
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| PubChem (CID) | 53341130 |
| ChemSpider | 25069631 |
| ChEMBL | CHEMBL1812717 |
| Chemical and physical data | |
| Formula | C22H17FN3O2S |
| Molar mass | 441.905 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
MK-4409 is a drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11nM, and both analgesic and antiinflammatory effects in animal studies. It was developed for the treatment of neuropathic pain and has progressed as far as early stage human clinical trials.[1][2]
See also
References
- ↑ Chobanian; et al. (10 April 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Med. Chem. Lett.
- ↑ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.